Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes

Ocular Therapeutix Inc. (NASDAQ:OCUL) shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular degeneration (AMD).

The stock is trading lower as data did not meet investor expectations.

STAT News reported that Axpaxli's durability advantage over the active control was smaller than investors had anticipated, potentially raising questions about its commercial outlook in wet age-related macular degeneration, a market with established effective therapies.

Eye Disorder Trial Data

Ocular Therapeutix shared topline results from the SOL-1 Phase 3 superiority trial of Axpaxli (OTX-TKI).

After a loading phase, the SOL-1 trial compared a single dose of Axpaxli (0.45 mg) to a single dose of Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) Eylea (aflibercept 2 mg).

The SOL-1 Phase 3 superiority trial demonstrated that 74.1% of subjects treated with Axpaxli maintained vision at Week 36, compared to 65.9% in the aflibercept arm, marking a notable risk difference of 17.5% (p=0.0006).

In addition to achieving the primary endpoint, Axpaxli showed either statistical significance or numerical superiority to aflibercept (2 mg) in key secondary and prespecified exploratory endpoints.

The trial also highlighted that 80.6% of subjects in the Axpaxli arm were rescue-free at Week 24, significantly outperforming the aflibercept group.

Axpaxli met its Week 52 durability assessment with high statistical significance.

The proportion of subjects who maintained vision at Week 52 was 65.9% in the Axpaxli arm compared to 44.2% in the aflibercept (2 mg) arm, with a risk difference of 21.1% compared to aflibercept (2 mg) subjects, and with an observed difference of 21.7%.

Sanofi SA (NASDAQ:SNY) was reportedly bidding for Ocular Therapeutix.

Next Steps

Ocular intends to submit a New Drug Application (NDA) based on SOL-1 data, subject to planned formal discussions with the U.S. FDA.

If approved, Axpaxli could be the first tyrosine kinase inhibitor (TKI) to be commercialized in wet AMD, and potentially the only therapy with a superiority label and best-in-disease durability.

The complementary SOL-R Phase 3 non-inferiority trial of Axpaxli in wet AMD will continue as planned, with topline data expected in the first quarter of 2027.

Technical Analysis

Currently, Ocular Therapeutix is trading 26.46% lower in premarket trading, reflecting a significant shift from its previous close. The stock has increased by 23.33% over the past 12 months, indicating a generally positive long-term trend despite recent volatility. Its 52-week range shows a high of $16.44 and a low of $5.79, positioning the stock closer to its lows than its highs.

The RSI level is not available, but the MACD status is also not provided, indicating a lack of clear momentum signals at this time. Without these indicators, traders should be cautious, as the absence of momentum signals can suggest uncertainty in price direction.

Analyst Consensus & Recent Actions

The stock carries a Buy Rating with an average price target of $21.00. Recent analyst moves include:

• Chardan Capital: Buy (Maintains Target to $21.00) (Dec. 9, 2025)
• Needham: Buy (Maintains Target to $20.00) (Dec. 8, 2025)
• HC Wainwright & Co.: Buy (Raises Target to $21.00) (Dec. 8, 2025)

OCUL Price Action: Ocular Therapeutix shares were down 25.45% at $6.62 during premarket trading on Tuesday, according to Benzinga Pro data.

Image via Shutterstock/ New Africa